ThinkstockThe conference season is starting to get into full swing, and for the top biotech stocks, that means an appearance at the American Society of Clinical Oncology yearly conference. Many of the…
ThinkstockBy any stretch of normal measurement in earnings season, Gilead Sciences Inc. (NASDAQ: GILD) should have been a rocketing stock on Wednesday. Gilead blew away earnings and revenue estimates. Its Sovaldi Hepatitis…
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN) have both reported earnings. This is a definite difference in how the reports look, and it could throw a wild card report…
ThinkstockBiotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off of momentum stocks in a reality check. The problem is that after…
Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many of them.…
Amgen submitted an SEC Filing showing that, as of April 1, one of its subsidiaries and a GlaxoSmithKline subsidiary have terminated part and amended part of a collaboration agreement from 2009.
Most investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs generally are looking for…
In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples in years are very attractive for many investors. Here are the top…
courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage…
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Thursday, March 27, 2014. They include Apple, BlackBerry, Chesapeake Energy, Citigroup and King Digital.
After retreating from many leading biotech and emerging pharmaceutical stocks in the previous two periods, short sellers returned in early March, especially in Celgene, Medivation and Pharmacyclics.
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a…
In a new report out from Jefferies, the analysts posted a complete list of the cheapest, on a P/E basis, of the top health care stocks to buy now. Investors concerned about…
In a new research report from Deutsche Bank, the equity strategists point that the companies that are maintaining and increasing share buybacks, plus maintaining and increasing dividends, are the stocks to buy…
The pricier the stock market gets, the more important it is for investors to keep a close eye on what they are paying for stocks. Flashy momentum stocks are great for traders,…
